NASDAQ:FBIO Fortress Biotech (FBIO) Stock Price, News & Analysis $1.96 +0.03 (+1.55%) Closing price 04:00 PM EasternExtended Trading$2.00 +0.04 (+2.30%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Fortress Biotech Stock (NASDAQ:FBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fortress Biotech alerts:Sign Up Key Stats Today's Range$1.91▼$1.9650-Day Range$1.71▼$2.1352-Week Range$1.33▼$2.36Volume108,928 shsAverage Volume263,005 shsMarket Capitalization$57.96 millionP/E RatioN/ADividend YieldN/APrice Target$21.00Consensus RatingBuy Company Overview Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. Read More Fortress Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreFBIO MarketRank™: Fortress Biotech scored higher than 52% of companies evaluated by MarketBeat, and ranked 528th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingFortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFortress Biotech has received no research coverage in the past 90 days.Read more about Fortress Biotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Fortress Biotech are expected to grow in the coming year, from ($3.28) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fortress Biotech is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fortress Biotech is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.10% of the float of Fortress Biotech has been sold short.Short Interest Ratio / Days to CoverFortress Biotech has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in Fortress Biotech has recently decreased by 4.79%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFortress Biotech does not currently pay a dividend.Dividend GrowthFortress Biotech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.10% of the float of Fortress Biotech has been sold short.Short Interest Ratio / Days to CoverFortress Biotech has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in Fortress Biotech has recently decreased by 4.79%, indicating that investor sentiment is improving. News and Social Media2.5 / 5News Sentiment0.47 News SentimentFortress Biotech has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Fortress Biotech this week, compared to 1 article on an average week.Search Interest9 people have searched for FBIO on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Fortress Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Fortress Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders27.90% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.51% of the stock of Fortress Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fortress Biotech's insider trading history. Receive FBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address FBIO Stock News HeadlinesFortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights1 hour ago | globenewswire.comJourney Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsAugust 12 at 4:01 PM | globenewswire.comOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should buy in this market, this token might just be it.August 14 at 2:00 AM | Crypto 101 Media (Ad)Fortress Biotech (FBIO) Expected to Announce Quarterly Earnings on TuesdayAugust 11 at 2:12 AM | americanbankingnews.comJourney Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11August 7, 2025 | globenewswire.comJourney Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025August 5, 2025 | globenewswire.comJourney Medical Corporation Announces Expanded Payer Coverage for Emrosi™July 14, 2025 | globenewswire.comFBIO Fortress Biotech, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comSee More Headlines FBIO Stock Analysis - Frequently Asked Questions How have FBIO shares performed this year? Fortress Biotech's stock was trading at $2.03 on January 1st, 2025. Since then, FBIO shares have decreased by 3.9% and is now trading at $1.95. How were Fortress Biotech's earnings last quarter? Fortress Biotech, Inc. (NASDAQ:FBIO) issued its quarterly earnings data on Monday, March, 31st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.79) by $0.53. The biopharmaceutical company had revenue of $15.12 million for the quarter, compared to the consensus estimate of $16.30 million. Fortress Biotech had a negative trailing twelve-month return on equity of 4,712.53% and a negative net margin of 71.24%. Read the conference call transcript. When did Fortress Biotech's stock split? Shares of Fortress Biotech reverse split on the morning of Tuesday, October 10th 2023.The 1-15 reverse split was announced on Monday, October 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Fortress Biotech's major shareholders? Fortress Biotech's top institutional shareholders include Shikiar Asset Management Inc. (0.94%), Envestnet Asset Management Inc. (0.57%), 180 Wealth Advisors LLC (0.31%) and Atria Investments Inc (0.30%). Insiders that own company stock include Lindsay A Md Rosenwald, Dov Klein and David Jin. View institutional ownership trends. How do I buy shares of Fortress Biotech? Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Fortress Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fortress Biotech investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), KALA BIO (KALA), Ovid Therapeutics (OVID), Lipocine (LPCN) and Comtech Telecommunications (CMTL). Company Calendar Today8/14/2025Last Earnings8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:FBIO CIK1429260 Webwww.fortressbiotech.com Phone(781) 652-4500Fax781-652-4545Employees170Year FoundedN/APrice Target and Rating Average Price Target for Fortress Biotech$21.00 High Price Target$26.00 Low Price Target$16.00 Potential Upside/Downside+971.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($2.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$46 million Net Margins-71.24% Pretax Margin-183.81% Return on Equity-4,712.53% Return on Assets-27.67% Debt Debt-to-Equity Ratio1.74 Current Ratio1.72 Quick Ratio1.55 Sales & Book Value Annual Sales$57.67 million Price / Sales1.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-32.67Miscellaneous Outstanding Shares29,570,000Free Float21,320,000Market Cap$57.96 million OptionableOptionable Beta1.76 Social Links 10 Stocks Set to Soar in Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:FBIO) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fortress Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.